Apolipoprotein A-V; a potent triglyceride reducer
2011 (English)In: Atherosclerosis, ISSN 0021-9150, E-ISSN 1879-1484, Vol. 219, no 1, 15-21 p.Article in journal (Refereed) Published
Since its discovery, apolipoprotein A-V has been considered to be a potent factor affecting plasma triglycerides (TG) in humans and mice. Several single nucleotide polymorphisms in the APOA5 gene are associated with increased TG levels in humans, and some nonsense mutations affecting protein structure predispose for familial hypertriglyceridemia and late onset chylomicronemia. It is not clear, how apoA-V decreases plasma TG. There are three major hypotheses: apolipoprotein A-V could work through (1) an intracellular mechanism affecting VLDL production in the liver, (2) stimulation of proteoglycan-bound lipoprotein lipase at the endothelium of capillaries in peripheral organs, or (3) enhancing the clearance of TG-rich lipoproteins via lipoprotein receptors in the liver. There is good evidence for a role of apoA-V in extracellular TG metabolism and increasing support for an additional function of ApoA-V as a receptor ligand. The intracellular role of apoA-V for lipoprotein assembly and secretion is still speculative. This review discusses these possible mechanisms.
Place, publisher, year, edition, pages
Elsevier , 2011. Vol. 219, no 1, 15-21 p.
Apolipoprotein A-V, Apolipoprotein A5, Plasma triglyceride metabolism, Lipoproteins, Lipoprotein lipase, Heparan sulfate proteoglycans
Cardiac and Cardiovascular Systems
Research subject Medical and Physiological Chemistry
IdentifiersURN: urn:nbn:se:umu:diva-45977DOI: 10.1016/j.atherosclerosis.2011.07.019PubMedID: 21831376OAI: oai:DiVA.org:umu-45977DiVA: diva2:436745